The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

JP Morgan attendees were told of Jazz Pharmaceuticals' plans to expand indications for two oncology drugs: zanidatamab and ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.

Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, PTD802.

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of PH284 for the treatment of cancer cachexia.

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s regulatory plans.

The $90m will be used to launch the second of two pivotal trials examining the company’s therapy for patients living with heart failure.

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.